3
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Idarubicin as treatment for Acute Myelogenous Leukemia in the elderly

, , , &
Pages 4-7 | Published online: 01 Jul 2009
 

Abstract

27 patients aged over 60 years with acute myelogenous leukemia (AML) were treated with a chemotherapy regimen consisting of a combination of idarubicin (IDA) and cytosine arabinoside (ARA-C) as the induction regimen, with etoposide and 6-thioguanine added in the post-remission phase. Inclusion criteria were no different from those commonly used for younger adults. In 7 cases AML was preceded by a previous myelodysplastic syndrome (MDS). The median age was 68 (range 61–74) and 15 patients (55.5%) achieved complete remission (CR) and in 10 HR CR was achieved after only one course of chemotherapy. All patients in CR experienced profound bone marrow hypoplasia, requiring intensive support.Extrahematological WHO grade 4 toxicity was not observed in any patient. Median disease-free and overall survival for patients in CR was 10 and 14 months, respectively. We conclude that the combination of IDA and ARA-C is highly effective in inducing CR in elderly AML, with acceptable toxicity.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.